Open access
Open access
Powered by Google Translator Translator

Internal Medicine

Omicron’s feeble attack on the lungs could make it less dangerous.

11 Jan, 2022 | 01:23h | UTC

Omicron’s feeble attack on the lungs could make it less dangerous – Nature

 

Diagnostics for COVID-19: moving from pandemic response to control.

8 Jan, 2022 | 23:33h | UTC

Diagnostics for COVID-19: moving from pandemic response to control – The Lancet

 

Commentary on Twitter

 

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

9 Jan, 2022 | 01:05h | UTC

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv

Commentary: An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older – News Medical

Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

 

[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

8 Jan, 2022 | 23:28h | UTC

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

 

Guideline: ADA 2022 Standards of Medical Care in Diabetes.

24 Dec, 2021 | 13:38h | UTC

Guideline Homepage: ADA 2022 Standards of Medical Care in Diabetes – American Diabetes Association

Introduction: Standards of Medical Care in Diabetes—2022

Summary of Revisions: Standards of Medical Care in Diabetes—2022

Standards of Medical Care in Diabetes—2022 Guideline Abridged for Primary Care Providers

Video Summary: Standards of Care in Diabetes – 2022

  1. Improving Care and Promoting Health in Populations
  2. Classification and Diagnosis of Diabetes 
  3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities
  4. Comprehensive Medical Evaluation and Assessment of Comorbidities
  5. Facilitating Behavior Change and Well-being to Improve Health Outcomes
  6. Glycemic Targets
  7. Diabetes Technology
  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes
  9. Pharmacologic Approaches to Glycemic Treatment
  10. Cardiovascular Disease and Risk Management
  11. Chronic Kidney Disease and Risk Management
  12. Retinopathy, Neuropathy, and Foot Care
  13. Older Adults
  14. Children and Adolescents
  15. Management of Diabetes in Pregnancy
  16. Diabetes Care in the Hospital
  17. Diabetes Advocacy

 

Commentaries on Twitter

 

AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.

8 Jan, 2022 | 23:18h | UTC

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee – Neurology

News Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.

8 Jan, 2022 | 23:10h | UTC

Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Clinical trial reveals that omega-3 fish oil supplements do not help prevent depression – Massachusetts General Hospital

 

Review: Large-vessel vasculitis.

8 Jan, 2022 | 22:50h | UTC

Large-vessel vasculitis – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Large-vessel vasculitis (if the link is paywalled, try this one)

 

In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 

Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.

17 Dec, 2021 | 09:48h | UTC

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Commentary on Twitter

 

NICE Guideline | Acute heart failure: diagnosis and management.

17 Dec, 2021 | 08:48h | UTC

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Related: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 

NICE Guideline | Type 2 diabetes in adults: management.

17 Dec, 2021 | 08:45h | UTC

Type 2 diabetes in adults: management – National Institute for Health and Care Excellence

Related: Guideline: ADA 2021 Standards of Medical Care in Diabetes

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Management of Hip Fractures in Older Adults: Evidence-Based Clinical Practice Guideline.

16 Dec, 2021 | 09:42h | UTC

Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline – American Academy of Orthopaedic Surgeons

Summary: Management of Hip Fractures in Older Adults – American Academy of Orthopaedic Surgeons

News Release: AAOS Updates Clinical Practice Guideline for Management of Hip Fractures in Older Adults

 

Recommendations for antibiotic selection for severe nosocomial infections.

16 Dec, 2021 | 09:40h | UTC

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

 

Review: Impact of obesity in critical illness.

16 Dec, 2021 | 08:45h | UTC

Impact of Obesity in Critical Illness – CHEST

 

Perspective: Introducing nephrocardiology.

16 Dec, 2021 | 08:31h | UTC

Introducing Nephrocardiology – Clinical Journal of the American Society of Nephrology

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.